SynthesisCancer reports (Hoboken, N.J.)2026
Frailty in Patients With Hematologic Malignancies and Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review.
Synthesis in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Frailty in Patients With Hematologic Malignancies and Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review.Cancer reports (Hoboken, N.J.) · 2026Pooled it
- Charting the Future of Canadian Adult Acute Myeloid Leukemia (AML) Laboratory Testing: A Canadian Leukemia Study Group Current State Mapping of Diagnostic AML Laboratory Practice.Current oncology (Toronto, Ont.) · 2026Article
- Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH-TC study.British journal of haematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHematopoietic stem cell transplantation (HSCT) is associated with significant morbidity and mortality. Frailty further increases these risks in recipients of HSCT. This systematic review analyzes the extent of frailty in patients with hematologic malignancies and patients undergoing HSCT, and explores the associations between frailty and age, and clinical outcomes.
methodsCINAHL (EBSCO), Embase (Ovid), and Medline were searched for quantitative studies including assessment tools aimed at identifying frailty or vulnerability. Two reviewers independently assessed eligibility, extracted data from the included articles, performed a quality appraisal, and analyzed the findings through narrative synthesis.
resultsOf the 5190 abstracts screened, 17 articles involving 17 different tools describing frailty were identified. Frailty was characterized as abnormal nutritional status, comorbidities, and an impact on social support, physical activity, and mental health. Frailty was associated with increased age but was also shown in younger patients. Moreover, frailty was associated with worse clinical outcomes.
conclusionsPatients with hematologic malignancies and patients undergoing HSCT were at risk of frailty, and frailty was associated with older age and worse clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.